This clinical trial is focused on studying two types of lupus that affect the skin: Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus. These conditions can cause rashes and lesions on the skin, and sometimes they may also involve other parts of the body. The study is testing a new treatment called BIIB059, which is given as an injection. The purpose of the study is to evaluate how effective and safe BIIB059 is in reducing the activity of skin disease in people who have these types of lupus and have not responded well to antimalarial treatments.

Participants in the study will receive either the BIIB059 injection or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, with regular check-ups to monitor the participants’ health and the effects of the treatment.

The trial is divided into two parts, and participants will be assessed using specific scores that measure the severity and activity of their skin condition. These scores help researchers understand how well the treatment is working. The study aims to provide valuable information about the potential benefits of BIIB059 for people with these challenging skin conditions. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.